Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914977 · ClinicalTrials.gov registry record · Phase 1
Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
A Phase 1 study of Acute Myeloid Leukemia and Acute Lymphocytic Leukemia, sponsored by Tara Lin.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02914977: Completed Phase 1 study of Acute Myeloid Leukemia and Acute Lymphocytic Leukemia, sponsored by Tara Lin.
NCT02914977 is a Phase 1 study of Acute Myeloid Leukemia and Acute Lymphocytic Leukemia that has completed, run by Tara Lin. The registered enrollment target is 18 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02914977, a Phase 1 study of Acute Myeloid Leukemia and Acute Lymphocytic Leukemia, has completed, sponsored by Tara Lin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
In this pilot study, eligible patients will be treated with 5 days of low dose daunorubicin for one cycle only. Any patient who receives treatment on this protocol will be evaluable for toxicity. Each patient will be assessed for the development of toxicity at all scheduled visits (Days 1-5). Following participation on this brief pharmacodynamic trial, patients can then proceed to other conventional or investigational therapies, as clinically indicated.
Conditions Studied
Interventions
- DRUG Daunorubicin
Study Locations (1)
Kansas
- University of Kansas Cancer Center - Clinical Research Center - Fairway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-11 |
| Est. Completion | 2021-07-15 |
| Phase | Phase 1 |
What the finished NCT02914977 record still lists
NCT02914977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Daunorubicin is the first listed.
NCT02914977 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT02914977 about?
NCT02914977 is a clinical study titled "Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia". In this pilot study, eligible patients will be treated with 5 days of low dose daunorubicin for one cycle only. Any patient who receives treatment on this protocol will be evaluable for toxicity. Each patient will be assessed for the development of toxicity at all scheduled visits (Days 1-5). Follow...
What is the current status of trial NCT02914977?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-11. Estimated completion is 2021-07-15.
What conditions does trial NCT02914977 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia.
What interventions are being tested in trial NCT02914977?
The interventions under investigation include: Daunorubicin (DRUG).
Who is sponsoring clinical trial NCT02914977?
This trial is sponsored by Tara Lin, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02914977 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02914977's enrollment target sits among peer trials
18 259th of 306 higher than 40 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia